XELOX in colorectal cancer: a convenient option for the future?

Lindsay, C.R. and Cassidy, J. (2011) XELOX in colorectal cancer: a convenient option for the future? Expert Review of Gastroenterology and Hepatology, 5(1), pp. 9-19. (doi: 10.1586/egh.10.90)

Abstract

XELOX is a 3-weekly chemotherapy combination of oral capecitabine and intravenous oxaliplatin. The central hypothesis that led to its development was that it would provide a convenient and cost-effective alternative to intravenous fluorouracil-based chemotherapy doublets, without compromising on anti-tumor efficacy. Recently its role in colorectal cancer has become more established in both the metastatic and adjuvant setting. Ongoing investigation of XELOX continues in a number of directions: its combination with novel biological agents, its efficacy and safety in the elderly, and the development of biomarkers that can predict its anti-tumor effect. This article provides a comprehensive and up-to-date synopsis of all pertinent clinical studies detailing this regimen and its promise for the future.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Cassidy, Professor James
• Authors: Lindsay, C.R., and Cassidy, J.
• College/School: College of Medical Veterinary and Life Sciences > School of Cancer Sciences
• Journal Name: Expert Review of Gastroenterology and Hepatology
• ISSN: 1747-4124